Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 42.61 1.49 (3.62%) Market Cap: 3.54 Bil Enterprise Value: 3.05 Bil PE Ratio: 0 PB Ratio: 24.36 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript

Nov 14, 2023 / 12:30PM GMT
Release Date Price: $38.3 (+8.47%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Great pleasure that I'd like to welcome our guests today, Emil Kakkis, the President and CEO of Ultragenyx. Thanks so much for joining us, Emil. This is going to be a fireside chat format.

Questions & Answers

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Maybe to start off for those who are new to the story, if you can provide a 1-minute intro to Ultragenyx.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Sure. I have to do that. Happy to be here in London again. Christmas already beginning. So Ultragenyx founded in 2010, we've been in business 13 years. We're a commercial company focused on rare diseases. We have 4 approved products generating $420 million, $450 million revenue this year. And we have 5 late-stage programs, Phase III programs and Phase II programs that are in a variety of indications. We've recently put out data at our Analyst Day on the 3 larger

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot